Does trimetazidine pretreatment affect cardiopulmonary bypass-induced inflammation during coronary artery grafting?

Besogul Y., Tunerir B., Colak O., Alatas O., Akyuz F., Aslan R.

PERFUSION, vol.16, no.9, pp.318-323, 2003 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 9
  • Publication Date: 2003
  • Journal Name: PERFUSION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.318-323
  • Eskisehir Osmangazi University Affiliated: Yes


Background: Cardiac surgery involving cardiopulmonary bypass is associated with reperfusion injury and an inflammatory process. In a previous study, we showed the potential myocardial protective effects of trimetazidine pretreatment by measuring the cardiac marker protein troponin T (TnT) during coronary bypass operations. However, it is not known whether trimetazidine has a preventive effect on the cardiopulmonary bypass-induced inflammation. The aim of the present study was to investigate whether pretreatment with trimetazidine, a cellular anti-ischemic agent can prevent the deleterious effects of cardiopulmonary bypass-induced inflammation.